Michael Wechsler, MD, MMSc, recounts the phase III trial of Mepolizumab on patients with eosinophilic granulomatosis with polyangiitis (EGPA).
The phase III trial of mepolizumab suggests that the drug is effective in reducing remissions, dependency on inhaled corticosteroids and several other measures that benefit patients with eosinophilic granulomatosis with polyangiitis. "All in all, we found that mepolizumab significantly improved outcomes in patients with EGPA. This is a rare disease with significant unmet need and patients oftentimes are looking to reduce corticosteroids to minimize exacerbations. Mepolizumab seems to have done that for a large proportion of these patients," Wechsler said.